Aniracetam attenuates the 5-HT2 receptor-mediated head-twitch response in rodents as a hallucination model

Drug Development Research

Volumn 44, Issue 4, 1998, Pages 131-139

  Tanaka, Yushiro ^a   Nakamura, Kazuo ^a   Kurasawa, Mitsue ^a  

^a NIPPON ROCHE RESEARCH CENTER   (Japan)

Author keywords

5 HT2 receptor; Aniracetam; Cholinergic serotonergic interaction; Head twitch response; Nootropics

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; 5 HYDROXYTRYPTOPHAN; ANIRACETAM; ANISIC ACID; CYPROHEPTADINE; IDEBENONE; METOCLOPRAMIDE; NOOTROPIC AGENT; ONDANSETRON; PROPENTOFYLLINE; RITANSERIN; SCOPOLAMINE; SCOPOLAMINE BUTYL BROMIDE; TACRINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; EXPERIMENTAL MODEL; HALLUCINATION; HEAD TWITCH; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT;

EID: 0031756608     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199808)44:4<131::AID-DDR1>3.0.CO;2-S     Document Type: Article

References (50)

1. 3 receptors mediate inhibition of acetylcholine release in cortical tissue. Nature 338:762-703.
2. Bhattacharya SK, Sen AP (1992): Effects of muscarinic receptor agonists and antagonists on rat brain serotonergic activity. J Neural Transm 90:241-247.
3. Broks P, Preston GC, Traub P, Poppleton C, Ward C, Stahl MC (1988): Modelling dementia: Effects of scopolamine on memory and attention. Neuropsychologia 26:685-700.
4. Cassel JC, Jeltsch H (1995): Serotonergic modulation of cholinergic function in the central nervous system: Cognitive implications. Neuroscience 69:1-41.
5. Corne SJ, Pickering RW (1967): A possible correlation between drug-induced hallucinations in man and a behavioural response in mice. Psychopharmacology 11:65-78.
6. 2A receptor response. Pharmacol Biochem Behav 55:387-396
7. Dellu F, Mayo W, Cherkaoui J, Le Moal M, Simon H (1991): Learning disturbances following excitotoxic lesion of cholinergic pedunculopontine nucleus in the rat. Brain Res 544:126-132.
8. Giovannini MG, Rodino P, Mutolo D, Pepeu G (1993): Oxiracetam and aniracetam increase acetylcholine release from the rat hippocampus in vivo. Drug Dev Res 28:503-509.
9. 2 involvement in the mechanism of action of hallucinogenic agent. Life Sci 35:2505-2511.
10. 2 serotonin receptors: Evidence for a lack of selectivity. J Med Chem 35:734-740.
11. Handley SL, Singh L (1986): Neurotransmitters and shaking behaviour - More than a 'gut-bath' for the brain? Trends Pharmacol Sci 7:324-328.
12. Himori N, Mishima K (1994): Amelioration by aniracetam of abnormalities as revealed in choice reaction performance and shuttle behavior. Pharmacol Biochem Behav 47:219-225.
13. Himori N, Watanabe H, Matsuura A, Umeda Y, Kuwahara T, Takemoto C, Takamiya M, Yajima T, Tanaka Y, Nakamura K (1986): General pharmacological properties of aniracetam, a cerebral insufficiency improver. Jpn Pharmacol Ther 14(Suppl 4):759-794.
14. Hirata K, Ono S (1994): Effects of metabolites of aniracetam on long-term potentiation in mossy fiber-CA3 synapses in the rat hippocampal slices. Jpn Pharmacol Ther 22:1837-1843.
15. Honma A, Ikeda K, Udo N, Sadamori M, Hasegawa K, Kuruma I, Nanjyo C, Uto M, Nakahara T, Fujita T (1986): Clinical phase I study of aniracetam. J Clin Ther Med 2:929-952.
16. Hörtnagl H, Potter PE, Hanin I (1987): Effect of cholinergic deficit induced by ethylcholine aziridinium on serotonergic parameters in rat brain. Neuroscience 22:203-213.
17. 3 receptors in rat brain using radioligand binding. Nature 330:746-748.
18. Kojima T, Atsumi Y, Ichise K, Uchiyama M, Shimazono Y (1983): A polysomnographic study of the delirious state caused by administration of biperiden. Psychiatry 25:197-206.
19. Kubota A, Funiya I, Kurasawa M (1986a): Pharmacological study of aniracetam. II. Choice reaction time-shortening action of aniracetam in aged rats (2) - Active metabolites, repeated treatment, sex difference. Jpn Pharmacol Ther 14(Suppl 4):721-727.
20. Kubota A, Kurasawa M, Furuya I (1986b): Pharmacological study of aniracetam. I. Choice reaction time-shortening action of aniracetam in aged rats (1) - Effective doses and reference drugs. Jpn Pharmacol Ther 14(Suppl 4):713-720.
21. Kubota A, Furuya I, Kurasawa M (1986c): Pharmacological study of aniracetam. III. Choice reaction time-shortening action of aniracetam in rat post-cerebrovascular disease deficiency model - SHR-SP. Jpn Pharmacol Ther 14(Suppl 4):729-732.
22. 2 receptor binding sites: Binding properties, brain distribution, and functional role. Mol Pharmacol 21:301-314.
23. Little JT, Broocks A, Martin A, Hill JL, Tune LE, Mack C, Cantillon M, Molchan S, Murphy DL, Sunderland T (1995): Serotonergic modulation of anticholinergic effects on cognition and behavior in elderly humans. Psychopharmacology 120:280-288.
24. Martin JR, Haefely WE (1993): Pharmacology of aniracetam: A novel pyrrolidinone derivative with cognition enhancing activity. Drug Invest 5(Suppl 1):4-49.
25. 2 antagonists on drug-induced impairment of passive avoidance response in mice: comparison with acetylcholinesterase inhibitors. Psychopharmacology 112:134-141.
26. Mayersohn M, Roncari G, Wendt G (1993): Disposition pharmacokinetics and metabolism of aniracetam in animals. Drug Invest 5(Suppl 1):73-95.
27. Muir JL, Everitt BJ, Robbins TW (1994): AMPA-induced excitotoxic lesions of the basal forebrain: A significant role for the cortical cholinergic system in attentional function. J Neurosci 14:2313-2326.
28. Muramatsu M, Ohashi JT, Usuki C, Araki H, Aihara H (1988): Serotonin-2 receptor-mediated regulation of release of acetylcholine by minaprine in cholinergic nerve terminal of hippocampus of rat. Neuropharmacology 27:603-609.
29. Nakajima T, Takahashi M, Okada T (1986): Pharmacological study of aniracetam. VI. Effects of aniracetam on muscarinic acetylcholine receptors in the rat hippocampus. Jpn Pharmacol Ther 14(Suppl 4):751-757.
30. Nakamura K, Kurasawa M, Tanaka Y (1998a): Scopolamine model of delirium in rats and reversal of the performance impairment by aniracetam. Drug Dev Res 43:85-97.
31. Nakamura K, Kurasawa M, Tanaka Y (1998b): Apomorphine-induced hypoattention in rats and reversal of the choice performance impairment by aniracetam. Eur J Pharmacol 342:127-138.
32. Otomo E, Hirai S, Hasegawa K, Araki G, Nishimura T, Inanaga K (1987): Usefulness of aniracetam for cerebrovascular disorders: Double-blind trial against Ca hopantenate. J Clin Exp Med 140:989-1016.
33. Otomo E, Hirai S, Terashi A, Hasegawa K, Tazaki Y, Araki G, Ito E, Nishimura T, Furukawa T (1991): Clinical usefulness of aniracetam for psychiatric symptoms in patients with cerebrovascular disorders: Double-blind trial in placebo. J Clin Exp Med 156:143-187.
34. Perry EK, Perry RH (1995): Acetylcholine and hallucinations: Disease-related compared to drug-induced alternations in human consciousness. Brain Cogn 28:240-258.
35. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH (1978): Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 25: 1457-1459.
36. Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA, Blessed G, Fairbairn AW, Tomlinson BE, Perry RH (1985): Cholinergic correlates of cognitive impairment in Parkinson's disease: Comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 48:413-421.
37. Perry EK, Kerwin J, Perry RH, Irving D, Blessed G, Fairbairn A (1990): Cerebral cholinergic activity is related to the incidence of visual hallucinations in senile dementia of Lewy Body type. Dementia 1:2-4.
38. Quattrochi JJ, Mamelak AN, Binder D, Williams J, Hobson LA (1993): Dose-related suppression of REM sleep and PGO waves by the serotonin-1 agonist eltoprazine, Neuropsychopharmacology 8:7-13.
39. Riekkinen P Jr, Jäkälä P, Sirviö J, Riekkinen P (1991): The effects of increased serotonergic and decreased cholinergic activities on spatial navigation performance in rats. Pharmacol Biochem Behav 39:25-29.
40. Robinson SE (1983): Effect of specific serotonergic lesions on cholinergic neurons in the hippocampus, cortex and striatum. Life Sci 32:345-353.
41. Saletu B, Grünberger J, Linzmayer L (1980): Quantitative EEC and psychometric analyses in assessing CNS-activity of Ro 13-5057 - A cerebral insufficiency improver. Meth Find Exp Clin Pharmacol 2:269-285.
42. 1A agonists. J Pharmacol Exp Ther 273:101-112.
43. Senin U, Parnetti L, Cucinotta D, Criscuolo D, Longo A, Marini G (1993): Clinical experience with aniracetam in the treatment of senile dementia of the Alzheimer's type and related disorders. Drug Invest 5(Suppl 1):96-105.
44. Spignoli G, Pepeu G, (1987): Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine. Pharmacol Biochem Behav 27:491-495.
45. Stancheva SL, Alova LG (1994): Biogenic monoamine uptake by rat brain synaptosomes during aging. Effects of nootropic drugs. Gen Pharmacol 25:981-987.
46. Voytko ML, Olton DS, Richardson RT, German LK, Tobin JR, Price DL (1994): Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J Neurosci 14:167-186.
47. Yamamoto T, Ueki S (1981): The role of central serotonergic mechanisms on head-twitch and backward locomotion induced by hallucinogenic drugs. Pharmacol Biochem Behav 14:89-95.
48. Yamamoto T, Tazoe N, Ueki S (1983): Effect of zotepine on head-twitch induced by L-5-hydroxytryptophan, mescaline and 2,5-dimethoxy-4-methylamphetamine in mice and rats. Jpn J Pharmacol 33:319-325.
49. Yamamoto T, Ohno M, Yatsugi S, Fujikawa Y, Ueki S (1992): Nootropic candidates inhibit head-twitches induced by mescaline in mice. Jpn J Pharmacol 59:419-421.
50. Yamazaki N, Nagaoka A, Nagawa Y (1985): Effect of idebenone on scopolamine-induced impairment of short-term memory in rats. Jpn J Psychopharmacol 5:321-328.